Elekta AB (OTCMKTS:EKTAY) Short Interest Update

Elekta AB (OTCMKTS:EKTAY) was the target of a large increase in short interest in May. As of May 29th, there was short interest totaling 1,732 shares, an increase of 154.7% from the May 14th total of 680 shares. Based on an average daily volume of 3,159 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.0% of the company’s stock are short sold.

Elekta Stock Up 0.9%

Shares of EKTAY traded up $0.05 during mid-day trading on Friday, hitting $5.56. 1,890 shares of the company’s stock were exchanged, compared to its average volume of 2,379. The company has a market cap of $2.05 billion, a PE ratio of -34.75 and a beta of 1.00. Elekta has a 52 week low of $4.35 and a 52 week high of $6.93. The company has a 50-day simple moving average of $5.96 and a 200 day simple moving average of $6.07. The company has a debt-to-equity ratio of 0.56, a current ratio of 0.95 and a quick ratio of 0.73.

Elekta (OTCMKTS:EKTAY) last released its quarterly earnings data on Thursday, May 28th. The company reported $0.06 EPS for the quarter. The company had revenue of $521.00 million during the quarter. Elekta had a positive return on equity of 10.67% and a negative net margin of 3.32%. On average, research analysts forecast that Elekta will post 0.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Zacks Research cut Elekta from a “hold” rating to a “strong sell” rating in a research note on Tuesday, June 2nd. Two research analysts have rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

About Elekta

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.